1. Home
  2. CALC vs ORIS Comparison

CALC vs ORIS Comparison

Compare CALC & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$5.92

Market Cap

63.0M

Sector

Health Care

ML Signal

HOLD

ORIS

Oriental Rise Holdings Limited Ordinary Shares

HOLD

Current Price

$0.09

Market Cap

3.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CALC
ORIS
Founded
2011
2014
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Farming/Seeds/Milling
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
63.0M
3.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
CALC
ORIS
Price
$5.92
$0.09
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$14.50
N/A
AVG Volume (30 Days)
134.2K
2.4M
Earning Date
11-12-2025
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
N/A
$12,317,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$237.10
Revenue Growth
N/A
N/A
52 Week Low
$1.42
$0.07
52 Week High
$5.34
$2.85

Technical Indicators

Market Signals
Indicator
CALC
ORIS
Relative Strength Index (RSI) 75.16 29.79
Support Level $4.64 $0.07
Resistance Level $5.34 $0.11
Average True Range (ATR) 0.49 0.01
MACD 0.08 -0.00
Stochastic Oscillator 95.11 31.58

Price Performance

Historical Comparison
CALC
ORIS

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

Share on Social Networks: